• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Greece·Healthcare·LAVI.AT
Share

Lavipharm S.A. Stocks

€ 1.45Last Updated 24.07.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

€ 281.37M

€ 1.45
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Lavipharm S.A. is a company that specializes in the comprehensive lifecycle of pharmaceutical, dermocosmetic, and general healthcare products, from initial research and development to manufacturing, importation, marketing, and distribution. Its operations span both the Greek domestic market and international territories. The company's diverse pharmaceutical offerings cater to numerous therapeutic areas, including cardiology, chronic pain management, oncology, central nervous system disorders, general medicine, gastrointestinal health, and urology. In addition to prescription medications, Lavipharm provides a range of over-the-counter (OTC) drugs such as antiseptics, analgesics, and anti-lice treatments, alongside various skincare solutions. This enterprise, headquartered in Paiania, Greece, was established in 1911.

Company Valuation

Overvalued
2/7

From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, 'expensive' on E

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

26.07.2026 21:33

Revolut Valued at $115 Billion and a Record-Breaking Deal in Asia: Key Takeaways on IPOs as of July 26

26.07.2026 15:01

AI Tools to Combat Cognitive Biases: How Investors Can Use Them

25.07.2026 16:01

Small caps last week: New Nasdaq rules, AI hurting Tripadvisor, Archer's rotorcraft

25.07.2026 13:50

Chevron Discussed with the U.S. How to Protect Its Interests in Kazakhstan from the Effects of the War — WSJ

25.07.2026 13:01

The "Three Seas" Risk Zone, Tesla Hit by Expenses, and "Odyssey" — the Driving Force Behind Movie Theaters

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026